Clinical, bacteriological and immunological follow-up of household contacts of leprosy patients from a post-elimination area - Antioquia, Colombia

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 6, 2009, Pages 935-936

  Cardona Castro, Nora ^a   Beltrán Alzate, Juan Camilo ^a   Romero Montoya, Marcela ^a  

^a Instituto Colombiano de Medicina Tropical   (Colombia)

Author keywords

Follow up; Household contacts; Leprosy patients; Post elimination region

Indexed keywords

EID: 70350295884     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000600021     Document Type: Article

References (14)

1. Amezcua ME, Escobar-Gutierrez A, Mayen E, Cazares JV 1987. Sensitivity and specificity of the FLA-ABS test for leprosy in Mexican populations. Int J Lepr Other Mycobact Dis 55: 286-292.
2. Cardona-Castro N, Beltrán C, Manrique R 2008. Survey to identify Mycobacterium leprae infected household contacts of patients from prevalent regions of leprosy in Colombia. Mem Inst Oswaldo Cruz 103: 332-336.
3. Cardona-Castro N, Restrepo-Jaramillo S, Gil de la Ossa M, Brennan P 2005. Infection by Mycobacterium leprae of household contacts of lepromatous leprosy patients from a post-elimination leprosy region of Colombia. Mem Inst Oswaldo Cruz 100: 703-707.
4. Cho SN, Yanagihara DL, Hunter SW, Gelber RH, Brennan PJ 1983. Serological specificity of phenolic glycolipid I from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun 41: 1077-1083.
5. Donoghue HD, Holton J, Spielgelman M 2001. PCR primers that can detect low levels of Mycobacterium leprae DNA. J Med Microbiol 50: 177-182.
6. Goulart IM, Bernardes Souza DO, Marques CR, Pimenta VL, Gonçalves MA, Goulart LR 2008. Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin Vaccine Immunol 15: 101-105.
7. Hernández E, Cardona-Castro N, Rodríguez G, Villegas S, Beltrán C, Kimura M, Vissa V, Gómez Y 2008. Estudio de resistencia a la rifampicina y la dapsona en tres pacientes con recurrencia de lepra. Rev Panam Salud Publica 23: 73-77.
8. Isenberg H 1992. Clinical microbiology procedures handbook, American Society for Microbiology, Washington, p. 7.2.2-7.2.4.
9. Lockwood DN 2002. Leprosy elimination a virtual phenomenon or a reality? BMJ 324: 1516-1518.
10. Lockwood DN, Kumar B 2004.Treatment of leprosy. BMJ 328: 1447-1448.
11. Meeker HC, Levis WR, Sersen E, Schuller-Levis G, Brennan PJ, Buchanan TM 1986. ELISA detection of IgM antibodies against phenolic glycolipid-I in the management of leprosy: a comparison between laboratories. Int J Lepr Other Mycobact Dis 54: 530-539.
12. Meima A, Smith W, van Ootmarssen G, Richardus JH, Habbema DF 2004. The future incidence of leprosy: a scenario analysis. Bull World Health Org 82: 373-380.
13. SIVIGILA 2008. Situación de la lepra en Colombia. Available from: www.minsalud.gov.co.
14. WHO World Health Organization 2006. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006-2010. Operational guidelines. Lepr Rev 77: 1-50.